633 Time to deterioration of patient-reported outcomes in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
I. Boere, B. Pothuri, Olena Sukhina, T. Myers, Valentina Tuninetti, A. A. Secord, Florian Heitz, Paul Nowicki, Annika Auranen, Nicole Nevadunsky, L. Gilbert, Michael J Callahan, L. Willmott, Michael A Gold, M. Powell, C. Mccourt, Veena Vincent, Veronika Simang, M. Mirza, N. Cloven
{"title":"633 Time to deterioration of patient-reported outcomes in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial","authors":"I. Boere, B. Pothuri, Olena Sukhina, T. Myers, Valentina Tuninetti, A. A. Secord, Florian Heitz, Paul Nowicki, Annika Auranen, Nicole Nevadunsky, L. Gilbert, Michael J Callahan, L. Willmott, Michael A Gold, M. Powell, C. Mccourt, Veena Vincent, Veronika Simang, M. Mirza, N. Cloven","doi":"10.1136/ijgc-2024-esgo.33","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":517822,"journal":{"name":"Oral Sessions","volume":"56 7","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral Sessions","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2024-esgo.33","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
